VENBIO PARTNERS LLC
Q4 2021 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001776382
· CRD 290045
· Exempt reporting adviser
$555.1M Reported Value Total
Exempt Reporting Adviser
WWW.VENBIO.COM
Source: Form ADV filed 2026-03-12
Reported value
$555.1M
Quarter over quarter
-52.7%
Holdings
9
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
David Pezeshki
Chief Financial Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2021 13F record
Q4 2021 13F filing summary
| Period of report | December 31, 2021 |
|---|---|
| Filed | February 14, 2022 |
| Form | 13F-HR |
| Reported value | $555.1M |
| Positions | 9 |
| Change in reported value | -44.7% |
| New positions | 1 |
| Exited positions | 1 |
| Position turnover | 20.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
9 | $495.9M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
7 | $519.4M |
|
Q1 2026 13F
Filed May 15, 2026
|
6 | $280.6M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
6 | $216.3M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
6 | $176.4M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
6 | $114.8M |
|
Q1 2025 13F
Filed May 15, 2025
|
7 | $123.6M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
7 | $170.7M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
6 | $194.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
6 | $231.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
5 | $281.9M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
7 | $667.2M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
8 | $352.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
7 | $276.3M |
|
Q1 2023 13F
Filed May 15, 2023
|
6 | $180.4M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
7 | $322.5M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
8 | $432.2M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
9 | $351.2M |
|
Q1 2022 13F
Filed May 16, 2022
|
10 | $451.1M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
9 | $555.1M |
12 earlier quarters on file — choose one from the quarter menu above.
Top 9 holdings · Q4 2021
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ALXO ALX ONCOLOGY HLDGS INC | $208.5M | 37.55% |
| 2 | HRMY HARMONY BIOSCIENCES HLDGS IN | $116.9M | 21.05% |
| 3 | VTYX VENTYX BIOSCIENCES INC | $99.5M | 17.93% |
| 4 | AKRO AKERO THERAPEUTICS INC | $45.9M | 8.28% |
| 5 | PHVS PHARVARIS N V | $33.1M | 5.97% |
| 6 | IMPL IMPEL NEUROPHARMA INC | $23.8M | 4.29% |
| 7 | ELEV ELEVATION ONCOLOGY INC | $15.7M | 2.83% |
| 8 | CMPI CHECKMATE PHARMACEUTICALS IN | $10.5M | 1.9% |
| 9 | VRNA VERONA PHARMA PLC | $1.1M | 0.2% |
Values as reported on the Q4 2021 Form 13F. Every position is in the holdings table below.